サイニクス オンコロジー・マーケット・アセスメントチームとKantarコンサルタントが注目する 米国臨床腫瘍学会 (ASCO) 2020 トピック ～尿路上皮がん、大腸がん、非小細胞肺がん、多発性骨髄腫、胃がん～

注目トピック

• 尿路上皮がん (Urothelial carcinoma)
  Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.
  Abstract #: LBA1

• 大腸がん(Colorectal cancer)
  Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study.
  Abstract #: LBA4
  
  A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
  Abstract #: 4000

• 非小細胞肺がん (NSCLC)
  Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
  Abstract #: LBA5
  
  Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
  Abstract #: 9504

• 多発性骨髄腫 (Multiple myeloma)
  Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.
  Abstract #: 8501

• 胃がん(Gastric cancer)
  Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).
  Abstract #: 4513